277MO Filgrastim versus pegfilgrastim as primary prevention for reduction of chemotherapy induced febrile neutropenia in Nepal

Abstract

Chemotherapy-induced neutropenia is a frequent complication of cytotoxic chemotherapy treatment. It increases the risk of infection and often leads to febrile neutropenia (FN). Development of FN may compromise the treatment response with substantial economic burden. Granulocyte colony-stimulating factor (GCSF) administration could prevent episodes of FN and its related complications. Filgrastim and pegfilgrastim are GCSFs approved for the reduction of neutropenia-related outcomes. This study compares filgrastim and pegfilgrastim as primary prevention for reduction of chemotherapy induced FN and its direct cost to the patients.